#1 Clinical Trials Search in Europe

Pegunigalsidase Alfa

Pegunigalsidase Alfa is an innovative enzyme replacement therapy (ERT) being studied in clinical trials for the treatment of Fabry disease. This drug aims to provide a new option for patients who may not respond well to existing treatments or cannot participate in other ongoing trials. The clinical studies are designed to evaluate the long-term safety, efficacy, and tolerability of Pegunigalsidase Alfa in adult patients with Fabry disease.

Table of Contents

What is Pegunigalsidase Alfa?

Pegunigalsidase alfa, also known by its research name PRX-102, is a new medication being developed to treat Fabry disease. It belongs to a class of treatments called enzyme replacement therapy (ERT)[1]. This means it’s designed to replace a specific enzyme that is missing or not working properly in people with Fabry disease.

What is Fabry Disease?

Fabry disease is a rare genetic disorder that affects how the body processes certain fats. People with Fabry disease lack an enzyme called alpha-galactosidase A, which leads to the buildup of fatty substances in various organs and tissues throughout the body. This can cause a wide range of symptoms and complications, including kidney problems, heart issues, and pain[2].

How Pegunigalsidase Alfa Works

Pegunigalsidase alfa is a recombinant human alpha-galactosidase A. In simpler terms, it’s a lab-made version of the enzyme that’s missing in people with Fabry disease. When given to patients, it helps break down the fatty substances that accumulate in their bodies, potentially reducing symptoms and slowing the progression of the disease[2][3].

Clinical Trials and Research

Pegunigalsidase alfa is currently being studied in several clinical trials to evaluate its safety and effectiveness. These trials are designed to answer important questions about the medication:

  • Long-term safety and efficacy: Researchers are studying how well the medication works and how safe it is when used for extended periods, sometimes up to 7 years[2][3].
  • Different dosing schedules: Some trials are looking at giving the medication every 2 weeks, while others are studying a 4-week schedule[2][3].
  • Effects on various aspects of Fabry disease: The studies are measuring how pegunigalsidase alfa affects kidney function, heart health, pain levels, and overall quality of life for patients[2][3].

Dosage and Administration

Based on the clinical trials, pegunigalsidase alfa is being studied in two main dosing regimens:

  1. 1 mg/kg body weight every 2 weeks: This dosage is being tested in some trials and is given as an intravenous (IV) infusion, which means it’s administered directly into a vein[1][2].
  2. 2 mg/kg body weight every 4 weeks: This higher dose given less frequently is also being studied and is administered as an IV infusion[3].

The exact dosage and schedule that might be recommended if the drug is approved will depend on the results of these studies.

Potential Benefits

While the full results of the clinical trials are not yet available, researchers are studying several potential benefits of pegunigalsidase alfa:

  • Improved kidney function: The trials are measuring changes in estimated glomerular filtration rate (eGFR) and protein levels in urine, which are indicators of kidney health[2][3].
  • Better heart health: Studies are looking at the effects on heart size and function[2][3].
  • Reduced pain: Researchers are tracking pain levels and the use of pain medication[2][3].
  • Improved quality of life: The trials are using questionnaires to assess overall quality of life for patients taking the medication[2][3].
  • Decreased levels of disease markers: The studies are measuring levels of substances in the blood (Lyso-Gb3 and Gb3) that are typically elevated in Fabry disease[2][3].

Safety and Side Effects

A primary focus of the ongoing clinical trials is to evaluate the safety of pegunigalsidase alfa. Researchers are carefully monitoring for any side effects or adverse reactions throughout the studies[1][2][3]. While specific safety data from these trials is not yet available, it’s important to note that all medications can potentially cause side effects. If pegunigalsidase alfa is approved for use, detailed safety information will be provided to patients and healthcare providers.

It’s worth noting that one of the trials is specifically designed to provide access to pegunigalsidase alfa for patients who cannot be adequately treated with currently approved medications or who are unable to participate in other ongoing clinical trials[1]. This suggests that researchers believe this new medication may offer benefits for some patients who haven’t responded well to existing treatments.

Aspect Details
Drug Name Pegunigalsidase Alfa (PRX-102)
Purpose Treatment of Fabry Disease
Administration Intravenous infusion
Dosage 1 mg/kg every 2 weeks or 2 mg/kg every 4 weeks
Trial Types Open-label extension studies
Primary Outcome Evaluation of treatment-related adverse events
Secondary Outcomes Kidney function, cardiac assessment, biomarkers, pain levels, symptom severity, quality of life
Trial Duration Up to 364 weeks (7 years) or until commercial availability
Patient Population Adult patients with Fabry Disease who completed previous studies

FAQ

  • What is Pegunigalsidase Alfa? Pegunigalsidase Alfa is a recombinant enzyme replacement therapy (ERT) designed to treat Fabry disease. It works by replacing the deficient enzyme, alpha-galactosidase A, in patients with Fabry disease.
  • How is Pegunigalsidase Alfa administered? Pegunigalsidase Alfa is administered through intravenous infusions. The dosage and frequency may vary depending on the specific clinical trial, ranging from 1 mg/kg every 2 weeks to 2 mg/kg every 4 weeks.
  • What are the main goals of the clinical trials for Pegunigalsidase Alfa? The main goals of these clinical trials are to evaluate the long-term safety, tolerability, and efficacy of Pegunigalsidase Alfa in adult patients with Fabry disease. Researchers are also studying its effects on kidney function, cardiac health, and quality of life.
  • How long do the clinical trials for Pegunigalsidase Alfa last? The duration of the clinical trials varies, but some studies last up to 364 weeks (about 7 years) or until the drug becomes commercially available to patients, whichever comes first.
  • What outcomes are being measured in these clinical trials? The trials are measuring various outcomes, including treatment-related adverse events, kidney function, cardiac assessments, biomarkers for Fabry disease, pain levels, symptom severity, and quality of life. These measurements help researchers understand the overall effectiveness and safety of Pegunigalsidase Alfa.

Ongoing Clinical Trials on Pegunigalsidase Alfa

  • Study on the Safety and Effects of Pegunigalsidase Alfa for Children and Adolescents with Fabry Disease

    Recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Austria France Norway Spain

  • Study on the Long-Term Safety and Effectiveness of Pegunigalsidase Alfa for Adults with Fabry Disease

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark Italy Norway

Glossary

  • Fabry Disease: A rare genetic disorder characterized by the buildup of a type of fat called globotriaosylceramide (Gb3) in body cells, leading to various complications.
  • Enzyme Replacement Therapy (ERT): A medical treatment that replaces a missing or deficient enzyme in the body with a functional version of that enzyme.
  • Pegunigalsidase Alfa: A recombinant form of the enzyme alpha-galactosidase A, used as an enzyme replacement therapy for Fabry disease.
  • Intravenous Infusion: A method of delivering medications directly into the bloodstream through a vein.
  • Glomerular Filtration Rate (eGFR): A measure of how well the kidneys are filtering waste from the blood.
  • Left Ventricular Mass Index: A measurement of the size and thickness of the heart's main pumping chamber, used to assess cardiac health.
  • Lyso-Gb3: A biomarker used to monitor the progression and treatment response in Fabry disease.
  • Protein/Creatinine Ratio (UPCR): A urine test that helps evaluate kidney function and detect kidney damage.
  • Mainz Severity Score Index (MSSI): A scoring system used to assess the severity of Fabry disease symptoms.
  • Quality of Life (EQ-5D-5L): A standardized measure of health-related quality of life used in clinical trials.

References